Five Prime Therapeutics, which is developing protein therapeutics for cancers and autoimmune diseases, raised $62 million by offering 4.8 million shares at $13, within the range of $12 to $14. Five Prime Therapeutics plans to list on the NASDAQ under the symbol FPRX. Five Prime Therapeutics initially filed confidentially on 6/14/2013. Jefferies, BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.
